1) Home oxygen therapy (HOT) improves survival in patients with hypoxemia, though adherence to guidelines and follow-up is only about 50% in many countries.
2) Continuous oxygen therapy (COT) given for over 15 hours daily increases survival by 2-4 years in COPD patients with low oxygen levels. Portable oxygen allows more activity but devices are still heavy.
3) International guidelines recommend COT for patients with oxygen levels below 7.3 kPa, but adherence varies, from 35-81% of eligible patients receiving treatment across different countries. Follow-up after starting COT is also inconsistent.
This document discusses long-term oxygen therapy (LTOT) and home oxygen therapy. It provides an overview of the terminology, scientific background, equipment, indications, and practical considerations of LTOT. It also includes two case studies examining whether a patient should start or continue LTOT. The document summarizes the effects of LTOT including improved survival, decreased hospitalizations, and improved quality of life for COPD patients. It addresses portable oxygen therapy and the prevalence of home oxygen therapy in different countries.
This document discusses home oxygen treatment. It provides an overview of the scientific evidence for indications and effects of oxygen therapy. It also reviews prevalence, devices, side effects, and practical considerations for home oxygen treatment in Denmark. A case study is presented on whether a 65-year-old woman with COPD exacerbation should start chronic oxygen therapy. Guidelines for initiating oxygen are outlined. Survival rates on oxygen are compared between countries.
Chemotherapy is the main treatment for disseminated cancers. It involves using multiple drugs in cycles to target rapidly dividing cancer cells. Common drugs include alkylating agents, antimetabolites, microtubule inhibitors, and monoclonal antibodies. Combination chemotherapy aims to maximize responses while avoiding overlapping toxicities. Doses are based on body surface area and adjusted for individual factors. Treatment intervals allow time for normal tissues to recover between cycles. Toxicities include myelosuppression, nausea/vomiting, and alopecia. Response is evaluated based on tumor shrinkage or progression.
How Smart Business Intelligence Yields Rapid Association GrowthThomas B. McClintock
After taking on the marketing challenges of ten participating organizations at MMCC ‘14, the Marketing Council’s “Doctor Is In” team has continued investigating more solutions since and has found success lies in interpreting and acting upon market data. Marketing connects people to solutions, and association marketers are uniquely positioned to make those connections across an entire vertical. But what happens when your entire vertical shifts, like healthcare or metal treatment? How can associations use Business Intelligence and Data Analytics to keep up with emerging trends and continue as a trusted resource, advisor or curator for key stakeholders? Join key association leaders who outpaced their competitors for an “Ask the Gurus” session to examine multiple best-in-class examples and distill strategies that can be scaled and applied to a wide variety of associations seeking rapid growth.
A presentation by Jacob Greisen at the 2017 meeting of the Scandinavian Society of Anaestesiology and Intensive Care Medicine.
All available content from SSAI2017: https://scanfoam.org/ssai2017/
Delivered in collaboration between scanFOAM, SSAI & SFAI.
1. Yes, the patient meets the criteria for home oxygen therapy with a PO2 <7.3 kPa at rest.
2. Portable oxygen for mobile hypoxemic patients is intended to:
- Increase hours on oxygen
- Increase daily activity
3. Studies have found no effect of adding ambulatory oxygen to pulmonary rehabilitation programs. Ambulatory oxygen alone does not improve exercise tolerance long-term.
This document discusses home oxygen therapy (HOT) in various countries. It provides an overview of the types of HOT, including continuous oxygen therapy (COT), short-term oxygen therapy (STOT), and nocturnal oxygen therapy (NOT). Clinical trials show that COT improves survival in COPD patients with low oxygen levels. Guidelines for COT recommend a minimum daily usage of 15 hours and follow-up every 3-6 months. Adherence to HOT varies significantly between countries, from 60% in Denmark to rates as low as 27% in some studies. Portable oxygen improves mobility and activity levels but is underutilized in many patients.
This document summarizes findings from the Danish Oxygen Register regarding long-term oxygen therapy (LTOT) in Denmark from 1994-2000. Some key findings include:
- The prevalence and incidence of COPD patients on LTOT increased and reached a plateau around 25 and 40 per 100,000 respectively.
- There was an increase in the proportion of cancer patients, older patients, and those using mobile oxygen units starting LTOT. The percentage treated over 15 hours daily and after hospital admission also rose.
- Around 20-25% of COPD patients on LTOT were still smoking despite the therapy.
- Survival rates improved over the period, however remained lower than other countries due to higher 6-
This document discusses long-term oxygen therapy (LTOT). It provides an overview of the terminology, scientific background, equipment, indications, and quality of LTOT treatment. Specifically:
1) It defines various types of home oxygen therapy including LTOT, short-term oxygen therapy (STOT), ambulatory oxygen therapy, and oxygen used for palliation of attacks of dyspnea.
2) It reviews studies showing the effects of LTOT on survival, health outcomes, and hospitalizations for COPD patients. LTOT is shown to increase survival by 2-4 years and decrease hospitalizations by 25% for qualifying patients.
3) It discusses considerations for starting, controlling, and ensuring quality of LT
1) Home oxygen therapy (HOT) improves survival in patients with hypoxemia, though adherence to guidelines and follow-up is only about 50% in many countries.
2) Continuous oxygen therapy (COT) given for over 15 hours daily increases survival by 2-4 years in COPD patients with low oxygen levels. Portable oxygen allows more activity but devices are still heavy.
3) International guidelines recommend COT for patients with oxygen levels below 7.3 kPa, but adherence varies, from 35-81% of eligible patients receiving treatment across different countries. Follow-up after starting COT is also inconsistent.
This document discusses long-term oxygen therapy (LTOT) and home oxygen therapy. It provides an overview of the terminology, scientific background, equipment, indications, and practical considerations of LTOT. It also includes two case studies examining whether a patient should start or continue LTOT. The document summarizes the effects of LTOT including improved survival, decreased hospitalizations, and improved quality of life for COPD patients. It addresses portable oxygen therapy and the prevalence of home oxygen therapy in different countries.
This document discusses home oxygen treatment. It provides an overview of the scientific evidence for indications and effects of oxygen therapy. It also reviews prevalence, devices, side effects, and practical considerations for home oxygen treatment in Denmark. A case study is presented on whether a 65-year-old woman with COPD exacerbation should start chronic oxygen therapy. Guidelines for initiating oxygen are outlined. Survival rates on oxygen are compared between countries.
Chemotherapy is the main treatment for disseminated cancers. It involves using multiple drugs in cycles to target rapidly dividing cancer cells. Common drugs include alkylating agents, antimetabolites, microtubule inhibitors, and monoclonal antibodies. Combination chemotherapy aims to maximize responses while avoiding overlapping toxicities. Doses are based on body surface area and adjusted for individual factors. Treatment intervals allow time for normal tissues to recover between cycles. Toxicities include myelosuppression, nausea/vomiting, and alopecia. Response is evaluated based on tumor shrinkage or progression.
How Smart Business Intelligence Yields Rapid Association GrowthThomas B. McClintock
After taking on the marketing challenges of ten participating organizations at MMCC ‘14, the Marketing Council’s “Doctor Is In” team has continued investigating more solutions since and has found success lies in interpreting and acting upon market data. Marketing connects people to solutions, and association marketers are uniquely positioned to make those connections across an entire vertical. But what happens when your entire vertical shifts, like healthcare or metal treatment? How can associations use Business Intelligence and Data Analytics to keep up with emerging trends and continue as a trusted resource, advisor or curator for key stakeholders? Join key association leaders who outpaced their competitors for an “Ask the Gurus” session to examine multiple best-in-class examples and distill strategies that can be scaled and applied to a wide variety of associations seeking rapid growth.
A presentation by Jacob Greisen at the 2017 meeting of the Scandinavian Society of Anaestesiology and Intensive Care Medicine.
All available content from SSAI2017: https://scanfoam.org/ssai2017/
Delivered in collaboration between scanFOAM, SSAI & SFAI.
1. Yes, the patient meets the criteria for home oxygen therapy with a PO2 <7.3 kPa at rest.
2. Portable oxygen for mobile hypoxemic patients is intended to:
- Increase hours on oxygen
- Increase daily activity
3. Studies have found no effect of adding ambulatory oxygen to pulmonary rehabilitation programs. Ambulatory oxygen alone does not improve exercise tolerance long-term.
This document discusses home oxygen therapy (HOT) in various countries. It provides an overview of the types of HOT, including continuous oxygen therapy (COT), short-term oxygen therapy (STOT), and nocturnal oxygen therapy (NOT). Clinical trials show that COT improves survival in COPD patients with low oxygen levels. Guidelines for COT recommend a minimum daily usage of 15 hours and follow-up every 3-6 months. Adherence to HOT varies significantly between countries, from 60% in Denmark to rates as low as 27% in some studies. Portable oxygen improves mobility and activity levels but is underutilized in many patients.
This document summarizes findings from the Danish Oxygen Register regarding long-term oxygen therapy (LTOT) in Denmark from 1994-2000. Some key findings include:
- The prevalence and incidence of COPD patients on LTOT increased and reached a plateau around 25 and 40 per 100,000 respectively.
- There was an increase in the proportion of cancer patients, older patients, and those using mobile oxygen units starting LTOT. The percentage treated over 15 hours daily and after hospital admission also rose.
- Around 20-25% of COPD patients on LTOT were still smoking despite the therapy.
- Survival rates improved over the period, however remained lower than other countries due to higher 6-
This document discusses long-term oxygen therapy (LTOT). It provides an overview of the terminology, scientific background, equipment, indications, and quality of LTOT treatment. Specifically:
1) It defines various types of home oxygen therapy including LTOT, short-term oxygen therapy (STOT), ambulatory oxygen therapy, and oxygen used for palliation of attacks of dyspnea.
2) It reviews studies showing the effects of LTOT on survival, health outcomes, and hospitalizations for COPD patients. LTOT is shown to increase survival by 2-4 years and decrease hospitalizations by 25% for qualifying patients.
3) It discusses considerations for starting, controlling, and ensuring quality of LT
The document discusses the impact of Denmark's national oxygen register on adherence to guidelines for long-term oxygen therapy (LTOT) in COPD patients. Some key findings from 1994-2000 include an increase in the prevalence and incidence of COPD patients on LTOT, more patients receiving mobile oxygen and starting LTOT after hospitalization. Documentation of hypoxemia improved but only about half of patients received follow-up and 20-25% still smoked. Survival rates increased over time but remained lower than other countries. The register data was not optimally utilized and direct feedback to doctors may help further improve LTOT guideline adherence.
7. Grunnkurset i lungesygd
Start LTOT
Ca. 80% af LTOT starter LTOT efter indl.
30-50% har “normaliseret” PaO2 efter 3 mdr
Information
Oxygen-system(er)
11. Grunnkurset i lungesygd
Prevalence and Incidence of LTOT in
Denmark 1994-2000
0
10
20
30
40
50
60
70
per100.000
31.10.94 31.12.95 31.12.96 31.12.97 31.12.98 31.12.99 31.12.00
Prevalence
Missing
Others
Cancer
COPD
0
10
20
30
40
50
60
70
per100.000
1995 1996 1997 1998 1999 2000
Incidence
Missing
Others
Cancer
COPD
12. Grunnkurset i lungesygd
Kvaliteten af iltbehandling i DK
Ca. 60% får ilt i 15-24 timer
Ca. 20% ryger (måske flere)
Ca. 50% har ikke iltmangel konstant
Ca. 40% kontrolleres årligt (20% korrekt)
13. Grunnkurset i lungesygd
Effect of oxygen and CO on
12-minute walking distance
Calverley PMA, BMJ 1981
580
600
620
640
660
680
700
720
740
760
Air Oxygen Air+CO Oxygen+CO
12-MWD
meter p<0.01 p<0.01 p<0.01
15 COPD; FEV1=0.56 L; PO2: 5.2-7.7 kPa
14. Grunnkurset i lungesygd
Smoking and LTOT
Effect? Probably
15-24 hrs/day? Not possible for heavy smokers
Safe? Not with everybody
Ethical aspects? Seretide to smokers?
15. Grunnkurset i lungesygd
Survival rates of new COPD patients on LTOT from
Denmark compared to patients from other countries
0
10
20
30
40
50
60
70
80
90
100
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Months
Cumulativesurvivalproportion(%)%)
Denmark (n=5659)
Sweden (n=403)
Belgium (n=270)
France (n=252)
Australia (n=505)
NOTT, COT (n=101)
Japan (n=4552)
16. Grunnkurset i lungesygd
Mobil ilt ved LTOT
Formål: mobilitet & ↑forbrug
Hvor mange kommer udendørs?Hvor mange kommer udendørs?
Hvem får mobil ilt?Hvem får mobil ilt?
Hvor meget bliver det brugt?Hvor meget bliver det brugt?
Udendørs
65%
Ikke udendørs
35%
Mobil ilt (38%) 48% 21%
Anvendt
timer/dag
1,32 1,13
>2 timer/uge,% 49 22
Ringbæk; Respir Med 1999
27% anvendte ikke ilten
17. Grunnkurset i lungesygd
Effekt og brug af mobil oxygen ved LTOT
LTOT: 3-12 måneder
Ekskluderede de ”dårligste”
konc.: 3 mdr. konc.
+ilt: 3 mdr. konc+air:
3 mdr.
Lacasse Y, ERJ 2005
18. Grunnkurset i lungesygd
Anvendelse, udeaktivitet,
QoL og gangfunktion
•Ingen effekt på QoL og 6 MWD
•Mobil system til mobile patienter øger antal timer med ilt
(Ringbaek 1999; Vergeret 1989)
19. Grunnkurset i lungesygd
Scenarier med desaturation
% iltmætning
95
90
85
nat Flyvning anstrengelse/anfald
7 timer 3-8 timer 0,5-2 timer
Ingen effekt Øget krav
Øget fokus
21. Grunnkurset i lungesygd
Korttids-effekten af iltterapi
ved anstrengelse
↓Borg Dyspnø score 0,5-1,0
↑fysiske formåen 5-20%
+
Vægten af ilt
Falde i iltslangen
Kosmetiske gener
-
• Ingen effekt af ilt før/efter anstrengelse Killen JWW, Thorax 2000
Lewis CA, ERJ 2003
McKeon JL, Thorax 1988
Stevenson NJ, Thorax. 2004
22. Grunnkurset i lungesygd
Langtids-effekten af iltterapi
ved anstrengelse (1)
Ingen effekt sammen med rehab.
Garrod R, Thorax 2000
Emtner M, AJRCCM 2003
Rooyackers JM, ERJ 1997
Wadell K, J Rehabil Med 2001
Puhan MA Respir Res 2004
23. Grunnkurset i lungesygd
Langtids-effekten af iltterapi
ved anstrengelse (2)
12-week double blinded randomized cross over study. Desat. ≤88%
4 L/min; 2 kg
Eaton ERJ 2002
24. Grunnkurset i lungesygd
Effekt af iltterapi på gangdistancen (acute)
og QoL (short-term)
Ved studie-afslutning ønskede 14 af 34 “responders” (41%) ikke
at fortsætte iltterapien pga. gener og besvær.
25. Grunnkurset i lungesygd
Conclusion (1)
↑ incidence and prevalence of COPD
most patients started after hospitalisation
Poor quality of adherence to guidelines
↓ survival compared to other countries
26. Grunnkurset i lungesygd
Conclusion (2)
↑ delivered mobile oxygen
Limited use of mobile oxygen. ↑total use
Ambulatory oxygen: +short-term effect but
no/limited long-term effect
Complaints from LTOT are common –
especially restricted autonomy and noise
from the conc.
27. Grunnkurset i lungesygd
Mobil ilt ved LTOT
Frankrig 1984-6; 159 ptt. m. KOL; ordin. >15 timer/dag; 12 MGD>200 m
Flow: 1,7 L/min i hvile og 2,2 L/min ved anstrengelse. Randomiseret.
Gr.A=75 Gr.B=84
Konc. Konc+lille fl.*(51) Flyd.(33)
Timer/dag: 14 hr 17 hr (ens B1 og B2)
<0,01
Udenfor med ilt: 55% 67%
Timer indenfor: ens
Aktivitet indenfor: ens
Aktivitet udenfor: ens
25% af bærbar ilt blev ikke benyttet og yderligere 15% blev kun
benyttet indenfor, dvs. 60% blev benyttet udenfor.
Klager over høj Vægt: Flasker: 50% Flyd.: 33%
*) 2½ L flaske + stroller (benyttet af 10%)
Vergeret J. Eur Respir J 1989
28. Grunnkurset i lungesygd
Langtids-effekten af iltterapi
ved anstrengelse (2)
26 KOL; FEV1 0,9 L; PO2: 7,8-10,9 kPa;
dyspnø ved anstrengelse; ikke krav til desat.
6 uger med hhv. O2 eller air; DB; cross-over
Air O2 P-værdi
Steps: 30 33 NS
Borg 4,3 4,0 NS
Desat. 4,1% 4,7% NS
CRDQ 86 91 NS
McDonald CF et al. AJRCCM 1995
In 1994 the prevalence of COPD was about 27/100.000. I the following years, it increased by about 50% to 42/100.000
The incidence of COPD increased from 20 to 25/100.00 during 5 years